Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rockwell Medical (RMTI) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Rockwell Medical (RMTI) over the last 17 years, with Q3 2025 value amounting to 9.95%.

  • Rockwell Medical's EBITDA Margin fell 167800.0% to 9.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.37%, marking a year-over-year decrease of 69500.0%. This contributed to the annual value of 0.6% for FY2024, which is 85800.0% up from last year.
  • According to the latest figures from Q3 2025, Rockwell Medical's EBITDA Margin is 9.95%, which was down 167800.0% from 8.39% recorded in Q2 2025.
  • Rockwell Medical's 5-year EBITDA Margin high stood at 6.84% for Q3 2024, and its period low was 54.52% during Q4 2021.
  • For the 5-year period, Rockwell Medical's EBITDA Margin averaged around 18.39%, with its median value being 9.95% (2025).
  • As far as peak fluctuations go, Rockwell Medical's EBITDA Margin skyrocketed by 443400bps in 2022, and later plummeted by -167800bps in 2025.
  • Quarter analysis of 5 years shows Rockwell Medical's EBITDA Margin stood at 54.52% in 2021, then skyrocketed by 81bps to 10.18% in 2022, then skyrocketed by 76bps to 2.48% in 2023, then increased by 15bps to 2.1% in 2024, then tumbled by -373bps to 9.95% in 2025.
  • Its EBITDA Margin was 9.95% in Q3 2025, compared to 8.39% in Q2 2025 and 7.19% in Q1 2025.